Diane M. Bsc Stone

Diane M. Bsc Stone

Auto-generated profile, based on publicly available information

Diane M. Bsc Stone

Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
SGScott S. Graves
Scott S. Graves
BGBoglarka Gyurkocza
Boglarka Gyurkocza
DSDiane M. Stone
Diane M. Stone
MPMaura H. Parker
Maura H. Parker
KAKraig Abrams
Kraig Abrams
RSRainer Storb
Rainer Storb

1 March 2015 in Transplantation Direct
Verified
Journal Article
Open access
SRSteven L. Rosinski
Steven L. Rosinski
RSRainer Storb
Rainer Storb
RSRoland K. Strong
Roland K. Strong
GSGeorge E. Sale
George E. Sale
DSDiane M. Bsc Stone
Diane M. Bsc Stone
SGScott S. Graves
Scott S. Graves
Background CD28 signal blockade after T cell receptor activation is under intense investigation as a tolerance-inducing therapy for transplantation. Our goal is to produce a CD28-specific reagent as a therapy for the prevention of graft rejection and graft-versus-host disease in the canine model of allogeneic hematopoietic cell transplantation. Methods We infused a monoclonal mouse anticanine CD28 antibody (1C6 mAb) into 4 dogs and a fragment of antigen-binding (1C6 Fab) into 2 dogs. Pharmacokinetics, pathology, cytokine release, and the crystal structure of 1C6 Fv were evaluated. Results Within an hour of an intravenous injection of the 1C6 mAb, the dogs became leukopenic and developed a steroid-refractory cytokine storm. Two of the dogs developed high fevers, one experienced diffuse alveolar hemorrhage and another developed gastrointestinal hemorrhage. The cytokine storm was characterized by elevated plasma levels of monocyte chemotactic protein-1, interferon gamma inducible protein-10, interleukin (IL)-10, IL-6, and tumor necrosis factor-α. In addition, 1 dog showed elevated levels of IL-2, IL-8, and IL-18. In contrast, infusion of 1C6 Fab was well tolerated without any side effects. Dry-coating 1C6 mAb onto tissue culture plates induced CD3-independent proliferation and tumor necrosis factor-α production. Crystal structure analysis revealed that 1C6 binds to canine CD28 in a manner different than previously reported for conventional agonistic or superagonistic antibodies. Conclusions These results indicate that dogs and humans develop a similar cytokine storm after infusion of anti-CD28 mAb, providing an appropriate large animal for further study. The 1C6 Fab warrants evaluation as a tolerance-inducing reagent in the canine model of allogeneic hematopoietic cell transplantation.

1 January 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SGScott S. Graves
Scott S. Graves
MPMaura H. Parker
Maura H. Parker
DSDiane Stone
Diane Stone
GSGeorge E. Sale
George E. Sale
SPSmitha P.S. Pillai
Smitha P.S. Pillai
RSRainer Storb
Rainer Storb
In murine model systems inducible costimulator (ICOS) signaling has been implicated in the formation of chronic graft-versus-host disease (GVHD). Previously, we showed that chronic GVHD can be reproducibly produced in the dog hematopoietic cell transplantation (HCT) model and that ICOS expression is upregulated on T cells in dogs with chronic GVHD. The goal of the present study was to determine whether administration of a short course of anti-canine ICOS mAb could alter the rapid and progressive course of chronic GVHD. Five dogs underwent HCT from dog leukocyte antigen mismatched unrelated donors after total body irradiation. Postgrafting immunosuppression consisted of methotrexate (days 1, 3, 6, and 11) and cyclosporine (days -1 through 78). Anti-ICOS mAb (3 injections, 72 hours apart) was administered upon diagnosis of GVHD. One dog failed to respond to anti-ICOS mAb therapy and succumbed to chronic GVHD in a time course similar to control untreated dogs. Overall, anti-ICOS-treated dogs experienced a significant prolongation in survival from the time of diagnosis of chronic GVHD compared with control dogs. Within the limitations of the number of study dogs we suggest that a short course of anti-ICOS mAb may be useful in the treatment of chronic canine GVHD.